Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib
Crohn's & Colitis 360 · 29.05.2023
DOI: 10.1093/crocol/otad031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 29.05.2023. Verfasst von Michael D Kappelman und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Primary and secondary non-response to Anti-Tumor Necrosis Factor (TNF) therapy is common in patients with ulcerative colitis (UC), yet limited research has compared the effectiveness of subsequent biological therapy.
Objective
We sought to compare the effectiveness of vedolizumab and tofacitinib in anti-TNF experienced patients with UC, focusing on patient-prioritized patient reported outcomes (PROs).
Methods
We conducted a prospective cohort study nested within the Crohn’s & Colitis Foundation’s IBD Partners and SPARC IBD initiatives. We identified anti-TNF experienced patients with UC initiating vedolizumab or ustekinumab and analyzed PROs reported approximately 6 months later (minimum 4 months, maximum 10 months). Co-primary outcomes were Patient Reported Outcome Measurement Information System (PROMIS) domains of Fatigue and Pain Interference. Secondary outcomes included PRO-2, treatment persistence, and need for colectomy.
Results
We compared 72 vedolizumab initiators and 33 tofacitinib initiators. At follow-up, Pain Interference (P=0.04), but not Fatigue (P=0.53,) was lower among tofacitinib initiators. A trend towards higher Social Role Satisfaction was not significant. The remainder of secondary outcomes (PRO2, treatment persistence, colectomy) did not differ between treatment groups.
Conclusion
Among anti-TNF experienced patients with UC, Pain Interference 4-10 months after treatment initiation was lower among tofacitinib users as compared to vedolizumab users. Many, but not all, secondary endpoints and subanalyses also favored favored tofacitinib. Future studies with larger sample sizes are needed to further evaluate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Yale School of Medicine, New Haven, Connecticut, USA.
- Crohn's & Colitis Foundation, New York, New York, USA.
- Healthcore, Wilmington, Delaware, USA.
- University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Janssen Research & Development, Titusville, New Jersey, USA.
ORCID-Profile: Michael D Kappelman
Zitieren
APA
Kappelman, M. D., Long, M. D., Zhang, X., Lin, F. C., Weisbein, L., Chen, W., Burris, J., Dorand, J. E., Parlett, L. E., Fehlmann, T., Brensinger, C. M., Haynes, K., Nair, V., Kaul, A. F., Dobes, A., & Lewis, J. D. (2023). Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otad031
Vancouver
Kappelman MD, Long MD, Zhang X, Lin FC, Weisbein L, Chen W, et al. Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib. Crohn's & Colitis 360. 2023. doi:10.1093/crocol/otad031
BibTeX
@article{Kappelman2023,
author = {Kappelman, Michael D and Long, Millie D and Zhang, Xian and Lin, Feng-Chang and Weisbein, Laura and Chen, Wenli and Burris, Jessica and Dorand, Jennifer E and Parlett, Lauren E and Fehlmann, Tara and Brensinger, Colleen M and Haynes, Kevin and Nair, Vinit and Kaul, Alan F and Dobes, Angela and Lewis, James D},
title = {Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib},
journal = {Crohn's & Colitis 360},
year = {2023},
doi = {10.1093/crocol/otad031}
}
EUVIMED